使用地诺单抗的注意事项

(Denosumab) is a bone resorption inhibitor with a unique mechanism of action. It inhibits the activation and development of osteoclasts, reduces bone resorption, and increases bone density. The FDA approved denosumab (Denosumab) for use in postmenopausal women with osteoporosis who are at high risk for fractures. It can help reduce the incidence of vertebral, non-vertebral and hip fractures in postmenopausal women with osteoporosis. This product is also used in patients for whom other current treatments are ineffective or intolerable to reduce the risk of fractures.

Precautions for Denosumab (Denosumab):

1. Hypocalcemia. Use of denosumab can cause severe hypocalcemia. Correct existing hypocalcemia before treatment with denosumab. Monitor calcium levels and administer calcium, magnesium, and vitamin D as necessary. Monitor levels more frequently when denosumab (Denosumab) is administered with other drugs that can also lower calcium levels. Advise patients to seek medical attention for symptoms of hypocalcemia.

2. According to clinical trials using lower doses of denosumab, patients with creatinine clearance less than 30 mL/min or receiving dialysis are at higher risk for severe hypocalcemia than patients with normal renal function. In a trial of 55 patients, both cancer-free and with varying degrees of renal impairment, receiving a single 60 mg dose of denosumab, 8/17 patients had a creatinine clearance less than 30 mL/min or underwent dialysis and had a corrected serum calcium level less than 8.0 mg/dL compared with 0/12 patients with normal renal function. The risk of hypocalcemia with the recommended dosing regimen of 120 mg every 4 weeks has not been evaluated in patients with creatinine clearance less than 30 mL/min or receiving dialysis.

3. Osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw, manifested by jawbone pain, osteomyelitis, osteitis, bone erosion, dental or periodontal infection, toothache, gingival ulceration, or gingival erosion, may occur in patients receiving denosumab. Persistent pain or slow healing of the back of the mouth or jawbone from dental surgery may also be signs of ONJ. In clinical trials, ONJ occurred in 2.2% of patients receiving denosumab, and of these patients, 79% had a history of tooth extraction, poor oral hygiene, or use of dental instruments. Perform oral examinations and appropriate preventive dentistry before starting denosumab and periodically during denosumab treatment. Remind patients about oral hygiene habits. Avoid invasive dental procedures during treatment with denosumab.

4. The risk of hypercalcemia increases after stopping treatment. In patients with giant cell tumor of bone and those with immature bone development, the risk of hypercalcemia is increased after discontinuation of denosumab, which can be serious. Tell your doctor right away if you have symptoms of hypercalcemia, such as nausea, vomiting, headache, and decreased alertness.

The above is the information about the careful implementation of (Denosumab) introduced to you by our medical companion team.

Recommended related hot articles: /newsDetail/74106.html